Compliance documents describe what should happen. Regulators and auditors measure what actually did. Shrink Manager™ operates at the execution layer between them — generating audit-verifiable records as a structured byproduct of daily work rather than a separate documentation burden.
Most compliance software operates at the documentation layer: defining what should happen, producing policy documents, and generating evidence after the fact. Most ERPs operate at the planning layer: coordinating resources, recording transactions, producing reports.
Regulators and buyers increasingly audit the execution layer — the work that actually happens between plan and record. Shrink Manager is purpose-built for that layer. It enforces workflow, gates artifact creation behind verified execution, and generates compliance evidence as a structured byproduct.
Each capability below corresponds to one or more of the eleven provisional patent applications filed with USPTO. The architecture is domain-general; the application work is where channel partners add vertical expertise.
Shrink Manager was built for and validated in regulated food manufacturing. The underlying patent architecture is domain-general and applies to any industry where execution must be audit-verifiable, time-stamped, and independently corroborated. The following are target verticals where the Company is actively scoping application with channel and industry partners.
Customs documentation, export licensing, sanctions and denied-party screening, and cross-border compliance records. The execution-layer architecture aligns naturally with trade compliance obligations where every transaction must be verifiable and every record must match the physical movement of goods.
Batch records, GMP documentation, serialization, and chain-of-custody for active pharmaceutical ingredient (API) and finished-product manufacturing. Temporal authenticity and dual-source verification patents align directly with FDA 21 CFR Part 11 electronic records requirements.
Design history files, device master records, and production records under FDA 21 CFR Part 820 and ISO 13485. The workflow-gated execution and execution-verified artifact patents apply to medical device manufacturing without material adaptation.
Industries with documented chain-of-custody, time-stamped execution requirements, or third-party attestation obligations are candidates for application. Laboratory quality control, clinical documentation, and financial transaction reconciliation have been preliminarily identified.
Shrink Software filed its first four foundational provisional applications in January and February 2026, covering the core execution-control architecture. Five expansion filings on April 18, 2026 extended the portfolio into adjacent commercial surfaces. Two forward-looking filings on May 27, 2026 extend the patent estate to the highest-frequency operational events on a regulated production floor — the shift boundary and the customer order itself — protecting next-generation capabilities currently in development. Together, the eleven applications protect a horizontal platform category rather than a single vertical product.
The foundational execution-control patterns protected by Waves 1 and 2 of the patent estate are not theoretical. They were developed inside a real multi-site regulated production operation, refined across 1M+ units annually, and validated against institutional buyer audits and FSMA 204 requirements. The architecture's maturity in food is the foundation for its application to adjacent regulated industries — and for the Wave 3 filings that extend the estate forward.
Shrink Software is actively scoping application of the execution-control architecture with channel and industry partners in regulated operations beyond food. Initial conversations are exploratory — we bring the architecture and the patent portfolio; you bring domain expertise and buyer relationships.
Questions? Email hello@shrinksoftware.com · Channel partners welcome